Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02LXJ
|
||||
| Former ID |
DNC007083
|
||||
| Drug Name |
3-(2-cinnamylphenyl)acrylic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528393] | ||
| Formula |
C18H16O2
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)C=CCC2=CC=CC=C2C=CC(=O)O
|
||||
| InChI |
1S/C18H16O2/c19-18(20)14-13-17-11-5-4-10-16(17)12-6-9-15-7-2-1-3-8-15/h1-11,13-14H,12H2,(H,19,20)/b9-6+,14-13+
|
||||
| InChIKey |
LDBYEQVSQBZSEH-BDXQXIFWSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin E2receptor, EP2 subtype | Target Info | Inhibitor | [528393] | |
| Prostaglandin E2 receptor EP3 subtype | Target Info | Inhibitor | [528393] | ||
| Prostaglandin E2 receptor, EP4 subtype | Target Info | Inhibitor | [528393] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction | |||||
| Pathways in cancer | |||||
| References | |||||